Bimatoprost

A glaucoma eye-drop that grows eyelashes as a side effect — packaged and FDA-approved for exactly that as Latisse. Unapproved "lash serum" versions of the same molecule also circulate.

Bimatoprost is a prostaglandin analogue. Its approved uses come from two different effects of the same molecule: it lowers pressure inside the eye by increasing fluid outflow, which treats glaucoma, and it extends the growth phase of eyelash follicles, which is why a separate lower-strength product is approved for eyelash growth. The eyelash indication was discovered as a side effect of the glaucoma treatment, which is a good reminder that a prostaglandin applied near the eye does several things at once.

Properly strong: randomized trials for both glaucoma and eyelash growth; the cosmetic indication is one of the rare beauty products with real RCT backing.

• STRONG for both approved indications — lowering intraocular pressure in glaucoma and ocular hypertension, and increasing eyelash prominence — on large randomised trials.
• The side effects that matter are not minor cosmetic annoyances. Permanent brown darkening of the iris is documented and is not reversible. Darkening of the eyelid skin occurs and is usually reversible.
• Periorbital fat atrophy — a hollowing and deepening of the eyelid socket that changes the appearance of the eye — is a recognised prostaglandin-associated effect that may be only partly reversible.
• NONE SHOWN for scalp hair growth. It has been studied for that and is not approved for it, and the eyelash result does not transfer.
• Substituting one product for the other is common and rests on a false assumption about relative strength. They differ in indication, application site, applicator and labelling, and neither was tested for the other use.

Applied topically to the eye or the lash line. The two products are NOT interchangeable, and the popular assumption about which is stronger is backwards: the US eyelash product is bimatoprost 0.03% while current US glaucoma labelling is 0.01%. They differ in approved indication, application site, applicator system and labelling. Effects on lashes require continued use and reverse when it stops; iris darkening does not.

Documented and specific: permanent iris darkening (brown pigmentation that does not reverse), reported periorbital fat atrophy and deepening of the eyelid sulcus with long use, lid skin darkening, and eye irritation. Unapproved versions lack the applicators and labeling that the approved product's safety record assumes.

• Anyone with glaucoma or other eye disease using it cosmetically without their ophthalmologist knowing
• Anyone with mixed-colour irises who would not accept permanent darkening
• Anyone pregnant or breastfeeding
• Anyone with active eye inflammation or a recent eye procedure

• Other prostaglandin eye drops, where combining can paradoxically reduce the pressure-lowering effect.
• Contact lenses, which the labelling addresses.
• Any existing eye condition or eye surgery history, which needs specialist input first.

• This is a prescription medicine and belongs with the prescriber who started it.
• Any change in iris colour — this is the effect that does not reverse, and it is more likely in people with mixed-colour irises.
• Any hollowing or change in the shape of the eye socket.
• Eye redness, itching or irritation, which are common.
• Anyone with glaucoma or eye disease using it cosmetically needs their ophthalmologist to know, since it alters the pressure the disease is monitored by.

Eyelash effects reverse over weeks to months and lashes return to their previous state — this is a maintenance treatment. Eyelid skin darkening usually reverses. Iris darkening does not, and periorbital fat atrophy may not fully. Anyone using it for glaucoma must not stop without their ophthalmologist, since the underlying pressure problem does not stop.

US: prescription-only (both Latisse and generic bimatoprost). The FDA has warned about cosmetic products containing prostaglandin analogs.

Papers about this compound, not proof of the claims above. A title says what was studied, which is sometimes a negative result or a different question entirely.

• Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study
  Br J Ophthalmol, 2026
• Phase 3, Randomized, Comparison Study of Intracameral Bimatoprost Implant 10 µg and Selective Laser Trabeculoplasty
  Am J Ophthalmol, 2025
• MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension
  Graefes Arch Clin Exp Ophthalmol, 2024

• Bimatoprost Implant: First ApprovalDrugs Aging · 2020
• Intracameral sustained release bimatoprost implants (Durysta)Semin Ophthalmol · 2022
• From Eye Care to Hair Growth: BimatoprostPharmaceuticals (Basel) · 2024
• Bimatoprost Ophthalmic Solution2026
• Bimatoprost for the treatment of eyelash, eyebrow and scalp alopeciaExpert Opin Investig Drugs · 2017
• Bimatoprost: a novel antiglaucoma agentCardiovasc Drug Rev · 2004
• Bimatoprost Intracameral Implant (Durysta®): A New Era in Glaucoma Management Through Sustained-Release InnovationDrug Des Devel Ther · 2025
• Bimatoprost in DermatologyIndian Dermatol Online J · 2018
• Bimatoprost - a reviewExpert Opin Pharmacother · 2009
• Bimatoprost: mechanism of ocular surface hyperemia associated with topical therapyCardiovasc Drug Rev · 2005
• BimatoprostOphthalmology · 2005
• Bimatoprost: a review of its use in open-angle glaucoma and ocular hypertensionDrugs Aging · 2009